CHMP gives nod to first pre-pandemic bird flu vacc
The European Medicines Agency (EMEA) recommended the authorization of the first pre-pandemic vaccine for humans against influenza caused by the H5N1 virus, a strain with the potential to evolve into a pandemic affecting humans. Prepandrix, from UK drug major GlaxoSmithKline, is a vaccine that is intended to trigger an immune response against the H5N1 strain before or during an officially-declared outbreak, in accordance with official guidance.
The EMEA noted that health authorities around the world are concerned that the next pandemic could occur at some point within the next few years and could be caused by the H5N1 strain. The recommendation has been sent to the European Commission for the adoption of a final marketing authorization decision.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze